Patent · US Active

Risk determination for neoplasia and cancer

US12331360B2 · kind B2 · utility

0Cited by

0References

33Claims

0Family size

Assignee

Oncgnostics GmbH · DE

Inventors

Matthias Durst · Hanau, DE
Ingo B. Runnebaum · Jena, DE
Martina Schmitz · Jena, DE
Alfred Hansel · Jena, DE

Key dates

Filing date	Sep 29, 2017
Grant date	Jun 17, 2025
Priority date	—
Expiry date	Sep 29, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/154
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Methods for the determination of the risk of developing neoplasia in a tissue, preferably anogenital tissue, showing no histopathological indications of neoplasia are described. The method is based on the determination of the methylation status of genomic DNA sequences associated with the genes ZNF671, ZNF154, ZNF776, ASTN1, BRINP2, DLX1, METAP1D and/or DLX2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.